New combination therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial is testing a new combination therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. The goal is to see if this treatment can shrink tumors or slow down the cancer, and it may offer a new option when standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have prostate cancer that has spread to other parts of the body, and it no longer responds to hormone therapy (this is called metastatic castration-resistant prostate cancer).
- You are expected to live at least 3 more months.
- You are able to be active (either fully active or restricted in physically strenuous activity but able to walk).
- You have not previously had cancer treatment using a type of drug called an antibody-drug conjugate (ADC) that uses a toxin called topoisomerase I inhibitor.
- You are willing to provide a sample of your tumor tissue (from a previous biopsy or surgery) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This study looks at how well the combination of two drugs, olaparib and abiraterone, works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if this treatment helps patients live longer and feel better in real-world settings.
This trial tests combining three treatments—a targeted radiation drug (177Lu-PSMA), a PARP inhibitor (olaparib), and an immunotherapy (pembrolizumab)—for men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink tumors and slow cancer growth.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial tests a new combination of two drugs for men with advanced prostate cancer that has stopped responding to standard hormone therapy or chemotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.